Fund Holdings — ARCH Venture Management, LLC

Total Portfolio Value
$492.36M
Total Bought
$28.69M
Total Sold
$22.94M
Net Transaction
+$5.75M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q2 2025
▲▼
Q3 2025
▲▼
Change
▲▼
Q2 2025
▲▼
Q3 2025
▲▼
Weight (%)
▲▼
Change
▲▼
RAPPORT THERAPEUTICS INC.(RAPP)3,728,7383,728,738042,433110,74422.49%+68,310
MAZE THERAPEUTICS INC.(MAZE)4,120,0534,120,053050,594106,83321.70%+56,239
BEAM THERAPEUTICS INC.(BEAM)4,540,1324,540,132077,228110,18922.38%+32,961
LYELL IMMUNOPHARMA INC.(LYEL)1,820,6342,759,072+938,43816,11344,8079.10%+28,695
GOSSAMER BIO INC.(GOSS)8,055,9168,055,91609,90921,1874.30%+11,278
ERASCA INC.(ERAS)11,055,55411,055,554014,09624,1014.89%+10,005
VIR BIOTECHNOLOGY INC.(VIR)12,916,66312,916,663065,10073,75414.98%+8,654
Q32 BIO INC.(FIXX)320,482320,48204786350.13%+157
CERO THERAPEUTICS HOLDINGS INC.22,38922,38902161140.02%-102
UNITY BIOTECHNOLOGY INC.1,004,8170-1,004,8173860—-386
VERVE THERAPEUTICS INC.2,008,8090-2,008,80922,5590—-22,559
Page 1 of 1
ARCH Venture Management, LLC — 13F Holdings — Q3 2025 | TickerTrail